On October 16, 2025, the Shanghai Municipal Medical Products Administration, Shanghai Municipal Health Commission, and Shanghai Customs jointly issued the Shanghai Pilot Work Plan for Service Guidance on Temporary Import of Clinically Urgent Drugs and Medical Devices. 《上海市关于临床急需药械临时进口服务指导工作方案（试行）》This new plan aims to streamline the temporary import process for clinically urgent drugs and medical devices in Shanghai, helping patients gain faster access to innovative medical products.

On November 20, 2025, the Department of Chemicals and Petrochemicals (DCPC) under the Ministry of Chemicals and Fertilizers of India issued multiple notifications announcing the withdrawal of six previously issued Quality Control Orders. This decision was made by the DCPC based on public interest considerations and in consultation with the Bureau of Indian Standards, in accordance with Section 16 of the Bureau of Indian Standards Act, 2016. The withdrawal took effect immediately upon announcement. Compliance actions already completed or initiated prior to the withdrawal remain unaffected.

To help stakeholders stay informed of the latest developments and gain insights into market trends, this article provides a systematic review and in-depth analysis of the cosmetic ingredient filings published by China’s National Medical Products Administration (NMPA) in November 2025. The report mainly covers the number of new ingredient filings during the month, basic information about the filing enterprises, the regional distribution of domestic filers, ingredients that have been filed multiple times, and interpretations of selected ingredients. It aims to offer valuable data support and information references for the cosmetics industry.

On December 3, 2025, the European Parliament and Council formally adopted Regulation (EU) 2025/2439, amending the chemical labeling regulations passed in 2024.

The recent approval of the Mycoprotein from Fusarium venenatum marks a significant milestone for Fushine Biotech. As the technical supporter, CIRS Group has assisted the company throughout the entire application process. Previously, CIRS had already supported Fushine in securing U.S. market access for the same ingredient through the GRAS Notice. These approvals —both in China and the United States—not only reflects Fushine Biotech’s strong R&D capacity and high product quality, but also underscores CIRS Group’s professional expertise in global food regulatory compliance.

To support the future implementation of the ESPR, this report outlines methods for defining and tracking Substances of Concern (SoC) in products and throughout their lifecycle.

On November 27, 2025, National Health Commission of the People’s Republic of China (NHC) issued an announcement (No. 7 of 2025) for “Three New Foods” with 14 products approved, including 3 new food raw materials, 8 new food additives, and 3 food-related products.

On 17 November 2025, the Scientific Committee on Consumer Safety (SCCS) of the European Union issued preliminary opinion (SCCS/1682/25) on Butylated Hydroxyanisole (BHA) (CAS No. 25013-16-5). The deadline for comments is set for 19 January, 2026.

According to Regulation (EC) No 1831/2003 (Feed Additives Regulation), feed additives refer to substances, microorganisms, or preparations—other than feed materials and premixes—that are intentionally added to feed or water to perform one or more functions. The EU has established a positive list of feed additives. To market a new feed additive not included in the positive list, an application for authorization must first be submitted to the EU authorities. Each authorization is valid for 10 years and may be renewed for an additional 10 years.

On November 24, 2025, the Taiwan Food and Drug Administration (TFDA) under the Ministry of Health and Welfare officially issued the testing method for Sudan dyes in cosmetics (Method No. RA03D015.001), which came into effect upon the date of publication.